Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxercalciferol

Next Previous
Drug Profile

Doxercalciferol

Alternative Names: 1 alpha-hydroxyergocalciferol; 1-alpha-D2; 1-alpha-Hydroxyvitamin D2; GZ-427397; Hectorol; TSA 870

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Wisconsin at Milwaukee
  • Developer Genzyme Corporation; Sanofi Genzyme
  • Class Calcium regulators; Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperparathyroidism
  • Discontinued Breast cancer; Colorectal cancer; Plaque psoriasis; Postmenopausal osteoporosis; Prostate cancer

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 Phase-III clinical trials in Hyperparathyroidism (In children, In adolescents) in USA (PO) (NCT02859896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top